
Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat
Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period
Updated On : 22 Jul 2026 | 11:37 PM ISTThe think tank says Indian generics may remain cost-competitive despite higher tariffs, but higher-value formulations and branded generics could face greater pressure
Updated On : 22 Jul 2026 | 2:51 PM ISTDonald Trump has proposed phased tariffs of up to 200% on imported generic drugs by 2028 to boost US manufacturing. Here's why the move matters for India's pharma sector and bilateral trade
Updated On : 22 Jul 2026 | 12:02 PM ISTBrokerages largely remain bearish on Dr Reddy's Labs shares following the Q1 earnings show.
The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.
The Trump administration last month proposed new tariffs of at least 10 per cent on 60 trading partners, citing what it said were lax forced-labor standards
Trump has seized on the cost of drugs as a key driver of affordability concerns ahead of the 2026 midterm elections